MedTrace Logo

AVERT™ Clinical Trial for Contrast Media Volume Reduction and Incidence of CIN

NCT01976299 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 578

Last updated 2017-02-28

Study results available
· View outcomes & findings →

Summary

The Osprey Medical AVERT System is indicated to reduce contrast media (CM) exposure to the kidneys during percutaneous coronary procedures thereby reducing the risk of contrast induced nephropathy (CIN).

Conditions

  • Contrast Induced Nephropathy (CIN)

Interventions

DEVICE

AVERT

Sponsors & Collaborators

  • Osprey Medical, Inc

    lead INDUSTRY

Principal Investigators

  • Roxana Mehran, MD, FACC · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2015-07-31
Completion
2015-09-30

Countries

  • United States
  • Australia
  • New Zealand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01976299 on ClinicalTrials.gov